The COVID-19 resource center, hosted by Elsevier, provides free information in English and Mandarin on the novel coronavirus. Elsevier grants permission to make all COVID-19-related research available in PubMed Central and other public repositories, with unrestricted access for research reuse and analysis. A multicenter retrospective study by Al-Samkari et al. (2020) examines the hemostatic and thrombotic complications in 400 hospitalized COVID-19 patients, primarily receiving standard-dose prophylactic anticoagulation. Key findings include: - **Thrombotic Complications**: The radiographically confirmed venous thromboembolism (VTE) rate was 4.8%, and the overall thrombotic complication rate was 9.5%. Arterial thrombosis occurred in 2.8% of patients. - **Bleeding Events**: The overall bleeding rate was 4.8%, with a major bleeding rate of 2.3%. In critically ill patients, the bleeding rate was 7.6%. - **Predictors**: Elevated D-dimer levels at initial presentation were predictive of coagulation-associated complications, critical illness, and death. Other markers predictive of thrombosis included elevated platelet count, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). - **Disseminated Intravascular Coagulation (DIC)**: Rare cases of DIC were observed, associated with significant bleeding manifestations. - **Conclusion**: The study suggests that while COVID-19 patients have elevated D-dimer levels, the observed bleeding rates indicate that empirical intensification of anticoagulation should be approached cautiously. Randomized trials are needed to determine the optimal dose and course of thromboprophylaxis in COVID-19 patients.The COVID-19 resource center, hosted by Elsevier, provides free information in English and Mandarin on the novel coronavirus. Elsevier grants permission to make all COVID-19-related research available in PubMed Central and other public repositories, with unrestricted access for research reuse and analysis. A multicenter retrospective study by Al-Samkari et al. (2020) examines the hemostatic and thrombotic complications in 400 hospitalized COVID-19 patients, primarily receiving standard-dose prophylactic anticoagulation. Key findings include: - **Thrombotic Complications**: The radiographically confirmed venous thromboembolism (VTE) rate was 4.8%, and the overall thrombotic complication rate was 9.5%. Arterial thrombosis occurred in 2.8% of patients. - **Bleeding Events**: The overall bleeding rate was 4.8%, with a major bleeding rate of 2.3%. In critically ill patients, the bleeding rate was 7.6%. - **Predictors**: Elevated D-dimer levels at initial presentation were predictive of coagulation-associated complications, critical illness, and death. Other markers predictive of thrombosis included elevated platelet count, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). - **Disseminated Intravascular Coagulation (DIC)**: Rare cases of DIC were observed, associated with significant bleeding manifestations. - **Conclusion**: The study suggests that while COVID-19 patients have elevated D-dimer levels, the observed bleeding rates indicate that empirical intensification of anticoagulation should be approached cautiously. Randomized trials are needed to determine the optimal dose and course of thromboprophylaxis in COVID-19 patients.